The Coming retweetledi

The world’s first anti-aging gene therapy has been injected into a human for the first time. In June 2026, Boston-based Life Biosciences announced that the first patient received a dose of their experimental therapy ER-100 in a Phase 1 clinical trial.
The treatment uses partial epigenetic reprogramming by delivering three Yamanaka factors (OCT4, SOX2, and KLF4) to restore aged or damaged cells to a more youthful state. It is currently being tested as an injection into the eye for age-related optic neuropathies, including open-angle glaucoma and non-arteritic anterior ischemic optic neuropathy (NAION).
This milestone marks the first time partial cellular reprogramming technology has been administered to a human. While the current trial focuses on safety and vision outcomes in the eye, it represents a major step toward broader anti-aging applications.
[Life Biosciences. (2026). Life Biosciences Announces First Patient Dosed in Phase 1 Trial of ER-100 for Optic Neuropathies. Company Press Release, June 9, 2026]

English







